NIH's MERS vaccine looks promising in mice

Investigators at the NIH have developed a new MERS vaccine that looks promising in mice. Focusing on the structure of a viral protein that the MERS virus uses to enter cells, the researchers developed a two-step, prime-boost process. The booster was given several weeks after the priming injection. The mice produced neutralizing antibodies when infected with MERS and rhesus monkeys--which weren't directly infected--were also protexted from the severe lung damage caused by MERS. Read more

Suggested Articles

With its phase 3 trial moving right along, Moderna is expecting efficacy data in November—likely after Pfizer and BioNTech, but before everyone else.

BioNTech expects a quick turnaround once the transaction closes and plans to produce up to 250 million doses of BNT162b2 in the first half of 2021.

Participation in clinical trials among Black people is low, FDA statistics show, even as drugmakers prioritize including them in COVID-19 shot trials.